Alpha mannosidosis is an extremely rare disease, which affects one in nearly 10, 00,000 people across the globe. Rise in the population has led to rise in the number of patients suffering from this diseases, which is supporting the growth of the global alpha mannosidosis market.
Progression of alpha mannosidosis eventually results in acute problems in tissues and organs of one’s body. Alpha mannosidosis has been classified into three different categories based on its type, namely Type I, Type II, and Type III. Classification of the diseases has been done according o the progression of the disease. Type I refers to the middle or the initial stage of the diseases, Type II is the moderate form of alpha mannosidosis and Type III is the most severe form. Type II is found most commonly.
Government Initiatives to Reduce Fatalities Due to Rare Diseases Spell Growth
This disease strike both women and men equally all over the world. There aren’t many treatment options available for alpha mannosidosis. Enzyme replacement therapy and bone marrow transplant are two of the treatment options of the disease. Out of the two, and bone marrow transplant is most widely used to treat the disease in patients.
A patient suffering from alpha-mannosidosis exhibits hearing loss, immuno defects, mental retardation, and it affects central nervous system as well.
Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2501
The global alpha mannosidosis market gains momentum from the rising investment by various governments in the treatment of rare diseases. For example, government of Australia has come up with a plan to assist patients suffering from various rare diseases in a bid to bring down the mortality rate due to those dieses. Apart from that, fee reductions and tax credits and market exclusivity of orphan drugs are also anticipated to propel the growth of the alpha mannosidosis market.
However, the global alpha mannosidosis market is likely to be adversely affected by the high cost involved with the development of those drugs.